Document is current
Any future updates will be listed below
-
Authors
Kario, Kazuomi
Ohbayashi, Hiroyuki
Hashimoto, Masami
Itabashi, Naoki
Kato, Mitsutoshi
Uchiyama, Kazuaki
Hirano, Kunio
Nakamura, Noriko
Miyamoto, Takahide
Nagashima, Hirotaka
Ishida, Hidenori
Ebe, Yusuke
Hatta, Tsuguru
Fukui, Toshiki
Katsuya, Tomohiro
Shimosawa, Tatsuo
Taguchi, Takashi
Tanabe, Ayumi
Ohishi, Mitsuru
,
- License Information
-
More Information
Article History
Received: 31 October 2024
Revised: 16 December 2024
Accepted: 18 December 2024
First Online: 28 March 2025
Compliance with ethical standards
:
: Daiichi Sankyo Co., Ltd., supported all authors with medical writing and article processing charges; all authors (except for T Shimosawa, T Taguchi, A Tanabe, and M Ohishi) with research funding; and K Kario, T Katsuya, T Shimosawa, and M Ohishi with advisory fees. K Kario received research grants from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; consulting fees from Sanwa Kagaku Kenkyusho Co., Ltd.; honoraria from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Viatris Inc.; and is an advisory board member of Daiichi Sankyo Co., Ltd. and Novartis Pharma K.K. Y Ebe received honoraria from Otsuka pharmaceutical Co., Ltd. T Hatta received honoraria from Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Kyowa Kirin Co., Ltd., Otsuka Phamaceutiacal Co., Ltd., and Novartis Pharma K.K. T Katsuya received honoraria from Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., AstraZeneca K.K., CureApp, Inc., Taisho Pharmaceutical Co., Ltd., and Moderna, Inc.; and payment for expert testimony from CureApp, Inc., and Novartis Pharma K.K. T Shimosawa received research funding from Takenaka Co., Ltd., FUJIFILM Corp., Nippon Boehringer Ingelheim Co., Ltd., Teijin Pharma Ltd., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd.; consultant fees from Sekisui Medical Co., Ltd. and EP Mediate Co., Ltd.; honoraria from Novartis Pharma K.K., Taisho Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi K.K., Mochida Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Aeon Co., Ltd., FUJIFILM Corp., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., Elsevier Japan K.K., Abbott Japan LLC., and Eiken Chemical Co., Ltd.; is a board member of Otsuka Medical Devices Co., Ltd. and Daiichi Sankyo Co., Ltd.; and is the chair of CVEM2023 and deputy director and educational seminars chair of the Japanese Society of Medical Use of Functional Foods, and the steering committee of Angiotensin Gordon Research Conference. T Taguchi and A Tanabe are employees of Daiichi Sankyo Co., Ltd. M Ohishi received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and Kowa Co., Ltd.
